Palatin Technologies Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Cranbury NJ United States (1996)

Organization Overview

First Clinical Trial
2006
NCT00425256
First Marketed Drug
2004
technetium (99m tc) fanolesomab (Neurospec)
First NDA Approval
2004
technetium (99m tc) fanolesomab (Neurospec)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Palatin | Palatin Technologies | PALATIN TECHNOLOGIES | Palatin Technologies, Inc | Palatin Technologies, Inc.

Active Ingredients

Marketed Drugs (2)

bremelanotide (Vyleesi) (2019)

technetium (99m tc) fanolesomab (Neurospec) (2004 NDA)

Drugs in Phase 3 Trials (2)

bremelanotide (Vyleesi) (5 trials)

pl9643 (2 trials)

Drugs in Phase 2 Trials (3)

pl3994 (2 trials)

pl-3994 (1 trial)

pl8177 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Disease (Phase 2)

Dry Eye Syndromes (Phase 2)

Eye Diseases (Phase 2)

Heart Failure (Phase 2)

Hypertension (Phase 2)

Hypokinesia (Phase 3)

Keratoconjunctivitis Sicca (Phase 2)

Sexual Dysfunction, Physiological (Phase 2)

Sexual Dysfunctions, Psychological (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 5